Brief: Oral Simufilam Slowed Cognitive Decline In A Randomized Withdrawal Trial Of Mild-To-Moderate Alzheimer's Disease

Filana Therapeutics

05/07/2023 14:22

July 5 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * ORAL SIMUFILAM SLOWED COGNITIVE DECLINE IN A RANDOMIZED
WITHDRAWAL TRIAL OF MILD-TO-MODERATE ALZHEIMER’S DISEASE
    * CASSAVA SCIENCES INC: DRUG EFFECTS FAVORED MILD
ALZHEIMER'S
DISEASE
    * CASSAVA SCIENCES INC - ORAL SIMUFILAM CONTINUES TO BE
SAFE, WELL
TOLERATED
    * CASSAVA SCIENCES INC: IN MILD ALZHEIMER'S, SIMUFILAM
IMPROVED
COGNITION SCORES OVER 6 MONTHS
    * CASSAVA SCIENCES INC - ORAL SIMUFILAM CONTINUES TO BE
SAFE, WELL
TOLERATED
    * CASSAVA SCIENCES INC: IN MILD ALZHEIMER'S, SIMUFILAM
STABILIZED
COGNITION SCORES OVER 18 MONTHS
    * CASSAVA SCIENCES INC: SIMUFILAM SLOWED COGNITIVE DECLINE
BY 38%
VERSUS PLACEBO OVER 6 MONTHS IN PATIENTS WITH MILD-TO-MODERATE
ALZHEIMER'S DISEASE
    * CASSAVA SCIENCES INC: CURRENTLY EVALUATING SIMUFILAM
TABLETS FOR
ALZHEIMER'S DISEASE DEMENTIA IN TWO PHASE 3 CLINICAL STUDIES
    * CASSAVA SCIENCES INC: PATIENT ENROLLMENT IS EXPECTED TO BE
COMPLETED FOR BOTH PHASE 3 STUDIES BY YEAREND 2023

Source text for Eikon:  ID:nGNX7nBNtN 
Further company coverage:  SAVA.O 

 ((reuters.briefs@thomsonreuters.com;))